Compare TEX & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEX | CELC |
|---|---|---|
| Founded | 1933 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.1B |
| IPO Year | N/A | 2017 |
| Metric | TEX | CELC |
|---|---|---|
| Price | $54.87 | $102.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | $57.50 | ★ $100.13 |
| AVG Volume (30 Days) | ★ 1.2M | 947.3K |
| Earning Date | 02-05-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.34 | N/A |
| Revenue | ★ $5,344,000,000.00 | N/A |
| Revenue This Year | $6.98 | N/A |
| Revenue Next Year | $4.25 | N/A |
| P/E Ratio | $23.33 | ★ N/A |
| Revenue Growth | ★ 4.60 | N/A |
| 52 Week Low | $31.53 | $7.58 |
| 52 Week High | $58.66 | $112.64 |
| Indicator | TEX | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 67.74 | 60.99 |
| Support Level | $51.20 | $97.27 |
| Resistance Level | $54.23 | $105.14 |
| Average True Range (ATR) | 1.51 | 5.04 |
| MACD | 0.58 | -1.29 |
| Stochastic Oscillator | 94.69 | 33.80 |
Terex is a global manufacturer of aerial work platforms, materials processing equipment, and specialty equipment for the waste, recycling, and utility industries. Its current composition is a result of numerous acquisitions over several decades to focus on a smaller group of light construction and other vocational equipment, having divested a handful of underperforming businesses, particularly in cranes and other lifting equipment. These remaining segments see heavy demand in nonresidential construction (aerial work platforms—40% sales), aggregates/mining (materials processing—30% sales), environmental, waste/recycling and utilities (environmental solutions group—30% sales).
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.